The FTC moves to block DNA sequencer Illumina’s acquisition of PacBio, calling company a ‘monopolist’

The Federal Trade Commission is challenging DNA sequencing giant Illumina’s proposed $1.2 billion purchase of rival Pacific Biosciences, alleging the acquisition would eliminate “a nascent competitive threat” to Illumina’s monopoly in deciphering genetic material.